Haemonetics (NYSE:HAE) Given New $92.00 Price Target at Citigroup

Key Points

• Citigroup raised Haemonetics’ price target to $92 from $79 while maintaining a Neutral rating, implying roughly 5% upside from the reported share price.
• Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and average target of $90.89; BTIG, Mizuho and Raymond James also issued bullish ratings or higher targets.
• Haemonetics exceeded quarterly expectations, reporting $1.14 in EPS and $339.4 million in revenue, up 5.5% year over year. Shares rose to $87.50, near the 52-week high, while the stock trades at a relatively high P/E of 43.32.

Haemonetics (NYSE:HAE - Get Free Report) had its price objective raised by investment analysts at Citigroup from $79.00 to $92.00 in a research report issued on Friday,Benzinga reports. The brokerage currently has a "neutral" rating on the medical instruments supplier's stock. Citigroup's price objective would suggest a potential upside of 5.14% from the company's current price.

HAE has been the subject of a number of other research reports. Mizuho boosted their price objective on Haemonetics from $85.00 to $90.00 and gave the company an "outperform" rating in a research report on Wednesday, July 15th. Raymond James Financial reaffirmed an "outperform" rating and issued a $105.00 target price on shares of Haemonetics in a research report on Friday. BTIG Research raised their target price on Haemonetics from $84.00 to $96.00 and gave the company a "buy" rating in a research note on Thursday. JPMorgan Chase & Co. boosted their price target on shares of Haemonetics from $62.00 to $86.00 and gave the company a "neutral" rating in a report on Friday. Finally, Robert W. Baird set a $96.00 price target on shares of Haemonetics in a research report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have issued a Hold rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $90.89.

Haemonetics Stock Performance

NYSE HAE traded up $2.48 during trading hours on Friday, reaching $87.50. The company's stock had a trading volume of 657,064 shares, compared to its average volume of 853,812. The company has a current ratio of 2.95, a quick ratio of 1.87 and a debt-to-equity ratio of 1.53. The business has a 50-day simple moving average of $76.59 and a 200 day simple moving average of $66.37. Haemonetics has a 52 week low of $47.31 and a 52 week high of $88.58. The stock has a market cap of $3.98 billion, a PE ratio of 43.32, a PEG ratio of 1.69 and a beta of 0.52.

Haemonetics (NYSE:HAE - Get Free Report) last posted its earnings results on Thursday, August 6th. The medical instruments supplier reported $1.14 EPS for the quarter, beating the consensus estimate of $1.08 by $0.06. The company had revenue of $339.38 million during the quarter, compared to analyst estimates of $327.86 million. Haemonetics had a return on equity of 27.30% and a net margin of 7.29%.The business's revenue was up 5.5% compared to the same quarter last year. During the same period in the prior year, the company earned $1.10 earnings per share. Equities research analysts predict that Haemonetics will post 5.21 earnings per share for the current fiscal year.

Institutional Trading of Haemonetics

Several hedge funds have recently added to or reduced their stakes in HAE. Kemnay Advisory Services Inc. bought a new position in shares of Haemonetics in the fourth quarter worth $26,000. Leonteq Securities AG bought a new stake in shares of Haemonetics during the fourth quarter valued at about $30,000. EverSource Wealth Advisors LLC raised its stake in shares of Haemonetics by 2,640.0% during the second quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier's stock valued at $31,000 after purchasing an additional 396 shares in the last quarter. Kestra Advisory Services LLC acquired a new stake in Haemonetics in the fourth quarter worth about $34,000. Finally, Kelleher Financial Advisors acquired a new stake in Haemonetics in the second quarter worth about $38,000. Institutional investors own 99.67% of the company's stock.

Key Stories Impacting Haemonetics

Here are the key news stories impacting Haemonetics this week:

• Positive Sentiment: Quarterly results exceeded expectations. Haemonetics reported fiscal Q1 2027 adjusted EPS of $1.14, above the $1.07–$1.08 consensus range, while revenue of $339.4 million topped estimates of $327.9 million and increased 5.5% year over year. Zacks earnings report
• Positive Sentiment: Management raised its outlook. The company now forecasts reported fiscal 2027 revenue growth of approximately 5% to 8%, supported by strength in the first quarter. The improved outlook gives investors greater confidence in near-term sales momentum. Seeking Alpha guidance report
• Positive Sentiment: BTIG Research raised its price target to $96 from $84 and maintained a Buy rating. The new target implies additional upside from current levels, reinforcing the bullish view following the earnings release. BTIG price target report
• Neutral Sentiment: JPMorgan raised its target to $86 from $62 but kept a Neutral rating. The revised target is close to the current share price, suggesting the firm views the stock as fairly valued despite the stronger results. Benzinga analyst report
• Negative Sentiment: The earnings beat initially produced a muted market reaction. Reports noted premarket weakness, potentially reflecting profit-taking and valuation concerns after the stock’s strong run toward its 52-week high. Haemonetics trades at roughly 42 times earnings, leaving limited room for execution shortfalls.

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company's offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company's product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source